Selected article for: "antibody response and effective antibody"

Author: Chiarini, Marco; Paghera, Simone; Moratto, Daniele; Rossi, Nicola De; Giacomelli, Mauro; Badolato, Raffaele; Capra, Ruggero; Imberti, Luisa
Title: Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection
  • Cord-id: 03dzqten
  • Document date: 2020_5_29
  • ID: 03dzqten
    Snippet: A multiple sclerosis patient infected by SARS-CoV-2 during fingolimod therapy was hospitalized with moderate clinical features, and recovered in 15 days. High levels of CCL5 and CCL10 chemokines and of antibody-secreting B cells were detected, while the levels other B- and T-cell subsets were comparable to that of appropriate controls. However, CD4+ and CD8+ cells were oligoclonally expanded and prone to apoptosis when stimulated in vitro. This study suggests that fingolimod-immunosuppressed pat
    Document: A multiple sclerosis patient infected by SARS-CoV-2 during fingolimod therapy was hospitalized with moderate clinical features, and recovered in 15 days. High levels of CCL5 and CCL10 chemokines and of antibody-secreting B cells were detected, while the levels other B- and T-cell subsets were comparable to that of appropriate controls. However, CD4+ and CD8+ cells were oligoclonally expanded and prone to apoptosis when stimulated in vitro. This study suggests that fingolimod-immunosuppressed patients, despite the low circulating lymphocytes, may rapidly expand antibody-secreting cells and mount an effective immune response that favors COVID-19 recovery after discontinuation.

    Search related documents:
    Co phrase search for related documents
    • lopinavir ritonavir hydroxychloroquine and lymphocyte neutrophil: 1, 2